2023 International Congress » Parkinsonism, Atypical: PSP, CBD

Meeting: 2023 International Congress

18F-Florzolotau PET Imaging Captures the Distribution Patterns and Regional Vulnerability of Tau Pathology in Progressive Supranuclear Palsy

FT. Liu, JY. Lu, XY. Li, YM. Sun, JJ. Wu, TC. Yen, QH. Zhao, CT. Zuo, J. Wang (Shanghai, China)

18F-Florzolotau PET imaging of tau pathology in the living brain of patients with corticobasal syndrome

FT. Liu, JY. Lu, XY. Li, YM. Sun, JJ. Wu, TC. Yen, QH. Zhao, CT. Zuo, J. Wang (Shanghai, China)

18f-PI-2620 tau PET neuroimaging, tau protein burden and 18f-PI-2620 tau autoradiography on human postmortem brain tissue in a PSP patient

ME. Erro, G. Martí-Andrés, A. Bronte, C. Caballero, J. Sánchez, E. Pérez-Martínez, S. Bullich, A. Mueller, MR. Luquin, J. Arbizu (Pamplona, Spain)

A Retrospective Review of Amantadine in Progressive Supranuclear Palsy

N. Mcfarland, R. Farrukh, S. Mahn (Gainesville, USA)

A tau-directed monoclonal antibody could alter the tau pathology of progressive supranuclear palsy

G. Beck, R. Yamashita, Y. Yonenobu, K. Ikenaka, S. Murayama, H. Mochizuki (Suita city, Japan)

Amyloid status differentiates synaptic loss and atrophy in Corticobasal Syndrome.

N. Holland, G. Savulich, P. Jones, D. Whiteside, D. Street, M. Naessens, M. Malpetti, Y. Hong, T. Fryer, T. Rittman, E. Mulroy, F. Aigbirhio, K. Bhatia, J. O'Brien, J. Rowe (Cambridge, United Kingdom)

An acoustic-perceptual analysis of speech in clinical PSP phenotypes.

G. Di Rauso, F. Cavallieri, A. Gessani, D. Fontanesi, S. Coniglio, V. Fioravanti, S. Contardi, E. Menozzi, S. Meletti, F. Antonelli, V. Rispoli, F. Valzania, C. Budriesi (Modena, Italy)

Atypical progression of motor symptoms in Facio-Scapulo-Humeral Dystrophy: clinical worsening or overlap?

D. Calisi, M. de Rosa, M. Russo, A. Thomas, M. Onofrj, S. Sensi (Chieti, Italy)

Beyond Parkinson´s disease and synucleinopathies: unexpected identification of prodromal corticobasal syndrome by the updated MDS research criteria for prodromal PD

K. Kulcsarova, E. Feketeova, J. Ventosa, M. Maretta, A. Lackova, M. Ostrozovicova, N. Lesko, M. Bekeová, P. Christová, S. Muranska, S. Mrazova, Z. Gdovinova, M. Skorvanek (Kosice, Slovakia)

Brain FDG-PET-MRI for early diagnosis of corticobasal syndrome

I. Guan, C. Stahl, K. Astudillo, T. Shepherd, S. Frucht, G. Riboldi (New York, USA)

CBS presenting rapidly progressive anterior operculum syndrome with suggested background pathology of 4-repeat tauopathy by tau PET: A case report

K. Nakamura, Y. Kuroha, M. Hatakeyama, A. Kimura, Y. Nakamura, Y. Murakami, M. Watanabe, H. Igarashi, T. Takahashi, H. Shimada (Niigata city, Japan)

Cell-specific MAPT gene expression is preserved in tau cytopathologies in Progressive Supranuclear Palsy

S. Forrest, S. Lee, N. Nassir, V. Sackmann, I. Martinez-Valbuena1, J. Li, A. Ahmed, L. Ittner, A. Lang, M. Uddin, G. Kovacs (Toronto, Canada)

Clinico-pathological correlations in atypical parkinsonism

R. Fumi, M. Theilmann Jensen, L. Wu, D. Vaughan, V. Chelban, Y. Goh, R. Real, A. Martinez Carrasco, E. Jabbari, A. Church, J. Coebergh, C. Kobylecki, U. Nath, M. Hu, A. Misbahuddin, J. Sharma, L. Massey, E. Capps, A. Robinson, F. Roncaroli, A. Lees, O. Ansorge, K. Allison, T. Warner, J. Rohrer, T. Revesz, Z. Jaunmuktane, J. Rowe, H. Houlden, H. Morris (London, United Kingdom)

Cognitive Interference in Postural Control as a Diagnostic and Prognostic Biomarker in Parkinsonian Disorders.

R. Lloyd, C. Fearon, R. Reilly (Dublin, Ireland)

Corticobasal Syndrome (CBS), Corticobasal Degeneration (CBD) and Progressive Supranuclear Palsy (PSP) Cohort in Central New York

M. Iqbal, T. Chabrashvili (Syracuse, USA)

Creation of a biobank of patients with Progressive Supranuclear Palsy and Corticobasal Syndrome in Argentina

B. Couto, G. Mizraji, M. Maza, S. Sargiotto, F. Greloni, I. Paez Paz, E. Avale, T. Falzone (Buenos Aires, Argentina)

Creutzfeldt-Jakob Disease misdiagnosed as Corticobasal degeneration

M. Elkasaby, C. Duffy, B. Appleby (Cleveland, USA)

Data-driven Clustering of Neurodegenerative diseases based on EEG Spectrum power-law decay: the DaCNES Study.

G. Mostile, R. Terranova, G. Carlentini, C. Terravecchia, G. Donzuso, G. Sciacca, C. Cicero, A. Luca, A. Nicoletti, M. Zappia (Catania, Italy)

Describing the syndrome: a comprehensive analysis of a large cohort of corticobasal syndrome with pathological correlation

D. Vaughan, M. Theilmann Jensen, D. Lux, L. Wu, Z. Jaunmuktane, T. Revesz, T. Lynch, M. Stamelou, K. Seppi, R. Vandenberghe, T. Warner, K. Bhatia, A. Lees, A. Church, N. Leigh, P. Taba, T. Matsalu, P. Mir, B. Ghosh, M. Picillo, J. Wallin, P. Svenningsson, Y. Compta, J. Rohrer, J. Rowe, H. Morris (London, United Kingdom)

Determinants of care partner burden in atypical parkinsonian syndromes

M. Ivancic, J. Shurer, M. Schmidt, V. Nesspor, M. Li, Y. Lin, R. Xu, G. Schumock, M. Sklerov, A. Pantelyat (Chapel Hill, USA)

Differential effect of MAPT haplotype on survival in CBD and PSP-SCB phenotype

A. Gharbi, I. Sghaier, I. Kacem, S. Mrabet, A. Souissi, A. Gargouri, A. Nasri, R. Gouider (Tunis, Tunisia)

Early-onset cortico-basal degeneration (CBD) due to a c.2092G>A MAPT mutation

M. Mata Alvarez-Santullano, L. Lopez-Manzanares, J. Lopez-Lozano, N. Villares, C. Magdaleno, C. Dela Torre (Madrid, Spain)

Effects of exergaming-based tai chi and eye movement training on balance and gait in progressive supranuclear palsy: a case report

Y. Levitan-Marcus (Tel Aviv, Israel)

Evaluation of a novel Phosphodiesterase 5 inhibitor as a potential therapeutic agent in P301S transgenic mouse model of tauopathy.

S. Elfarrash, S. Eldusoky, M. Abdel-Halim, M. Salama, S. El-Khodery, M. Youssef (Mansoura, Egypt)

Identifying a path to improve diagnostic delay and access to care for PSP, CBS, and MSA

M. Bruno, F. Ali, M. Dale, M. Schmidt, M. Comeau, C. Spears, J. Shurer (Honolulu, USA)

Impulse control disorder related to dopaminergic therapy in progressive supranuclear palsy

T. Thammongkolchai, P. Termsarasab (Bangkok, Thailand)

Increased MD and decreased FA reflect cognitive impairment in PSP

S. Kannenberg, AC. Hausmann, A. Schnitzler, CJ. Hartmann, C. Rubbert, J. Caspers (Düsseldorf, Germany)

Introducing the molecular subtyping of Progressive Supranuclear Palsy: a proof of concept

I. Martinez-Valbuena, S. Lee, E. Santamaria, J. Fernandez-Irigoyen, B. Couto, N. Reyes, H. Tanaka, S. Forrest, A. Kim, H. Qamar, J. Li, A. Karakani, K. Senkevich, E. Rogaeva, N. Visanji, A. Lang, G. Kovacs (Toronto, Canada)

Localizing a brain network of progressive supranuclear palsy

E. Ellis, J. Morrison-Ham, E. Younger, J. Joutsa, D. Corp (Melbourne, Australia)

MRI morphometry and regional hypometabolism in the clinical predominance-types of Progressive Supranuclear Palsy

H. Chovatiya, K. Pillai, R. Kamble, S. Santhamma, P. Rajeswari, M. Chacko, A. Kishore (Kochi, India)

Neurofilament light chain, tau-PET and microglia-PET predict clinical progression in amyloid-negative corticobasal syndrome

C. Palleis, N. Franzmeier, E. Weidinger, S. Katzdobler, N. Albert, O. Sabri, H. Barthel, R. Rupprecht, BS. Rauchmann, R. Perneczky, C. Haass, J. Levin, M. Brendel, GU. Hoeglinger (Munich, Germany)